Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419989 | 0.78 | RARB (0.36) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL19342971 | 0.74 | RARB (0.33) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL12715248 | 0.74 | RXRA (0.35) | — | |
| SCHEMBL2223568 | 0.73 | RARB (0.53) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL671020 | 0.73 | RARB (0.35) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL19342902 | 0.73 | RARB (0.44) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL19342973 | 0.72 | RARB (0.34) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL19343464 | 0.72 | RARB (0.34) | CYP26A1CYP3A4RARARARBRARG | |
| SCHEMBL16844662 | 0.72 | — | — | |
| SCHEMBL19342962 | 0.71 | RARB (0.48) | CYP26A1CYP3A4RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | claimed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | claimed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | claimed |
| CN-107176945-B | Retinoid compound, preparation method, intermediate and application thereof | 中国科学院上海有机化学研究所 | 2021-06-08 | — | — | CN | disclosed |
| US-20200216407-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-09 | — | — | US | disclosed |
| US-20200216407-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-09 | — | — | US | disclosed |
| US-10556879-B2 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADMENY OF SCIENCES (CN) | 2020-02-11 | — | — | US | disclosed |
| US-10556879-B2 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADMENY OF SCIENCES (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-03-28 | — | — | US | disclosed |
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-03-28 | — | — | US | disclosed |
| EP-3428155-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2019-01-16 | — | — | EP | disclosed |
| WO-2015107542-A2 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205950-A1 | Process for the preparation of Tazarotene | DHPS, COASY, STS | CYP26A1 970/4885CYP3A4 102/4885RARA 1663/4885 |
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | RARA, RARB, RARG | CYP26A1 77/4885CYP3A4 882/4885RARA 1/4885 |
| US-10556879-B2 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof | RARA, RARB, RARG | CYP26A1 77/4885CYP3A4 882/4885RARA 1/4885 |
| US-20200216407-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | RARA, RARB, RARG | CYP26A1 77/4885CYP3A4 882/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.